Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Genetic Testing Market 

5.1. COVID-19 Landscape: Genetic Testing Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Genetic Testing Market, By Test

8.1. Genetic Testing Market, by Test Type, 2023-2032

8.1.1. Carrier Testing

8.1.1.1. Market Revenue and Forecast (2020-2032)

8.1.2. Predictive Testing

8.1.2.1. Market Revenue and Forecast (2020-2032)

8.1.3. Diagnostic Testing

8.1.3.1. Market Revenue and Forecast (2020-2032)

8.1.4. Prenatal & Newborn Testing

8.1.4.1. Market Revenue and Forecast (2020-2032)

8.1.5. Nutrigenomics

8.1.5.1. Market Revenue and Forecast (2020-2032)

8.1.6. Pharmacogenomics

8.1.6.1. Market Revenue and Forecast (2020-2032)

8.1.7. Others

8.1.7.1. Market Revenue and Forecast (2020-2032)

Chapter 9. Global Genetic Testing Market, By Disease

9.1. Genetic Testing Market, by Disease, 2023-2032

9.1.1. Cancer

9.1.1.1. Market Revenue and Forecast (2020-2032)

9.1.2. Alzheimer’s

9.1.2.1. Market Revenue and Forecast (2020-2032)

9.1.3. Thalassemia

9.1.3.1. Market Revenue and Forecast (2020-2032)

9.1.4. Cystic Fibrosis

9.1.4.1. Market Revenue and Forecast (2020-2032)

9.1.5. Huntington’s Disease

9.1.5.1. Market Revenue and Forecast (2020-2032)

9.1.6. Duchenne Muscular Dystrophy

9.1.6.1. Market Revenue and Forecast (2020-2032)

9.1.7. Others

9.1.7.1. Market Revenue and Forecast (2020-2032)

Chapter 10. Global Genetic Testing Market, Regional Estimates and Trend Forecast

10.1. North America

10.1.1. Market Revenue and Forecast, by Test (2020-2032)

10.1.2. Market Revenue and Forecast, by Disease (2020-2032)

10.1.3. U.S.

10.1.3.1. Market Revenue and Forecast, by Test (2020-2032)

10.1.3.2. Market Revenue and Forecast, by Disease (2020-2032)

10.1.4. Rest of North America

10.1.4.1. Market Revenue and Forecast, by Test (2020-2032)

10.1.4.2. Market Revenue and Forecast, by Disease (2020-2032)

10.2. Europe

10.2.1. Market Revenue and Forecast, by Test (2020-2032)

10.2.2. Market Revenue and Forecast, by Disease (2020-2032)

10.2.3. UK

10.2.3.1. Market Revenue and Forecast, by Test (2020-2032)

10.2.3.2. Market Revenue and Forecast, by Disease (2020-2032)

10.2.4. Germany

10.2.4.1. Market Revenue and Forecast, by Test (2020-2032)

10.2.4.2. Market Revenue and Forecast, by Disease (2020-2032)

10.2.5. France

10.2.5.1. Market Revenue and Forecast, by Test (2020-2032)

10.2.5.2. Market Revenue and Forecast, by Disease (2020-2032)

10.2.6. Rest of Europe

10.2.6.1. Market Revenue and Forecast, by Test (2020-2032)

10.2.6.2. Market Revenue and Forecast, by Disease (2020-2032)

10.3. APAC

10.3.1. Market Revenue and Forecast, by Test (2020-2032)

10.3.2. Market Revenue and Forecast, by Disease (2020-2032)

10.3.3. India

10.3.3.1. Market Revenue and Forecast, by Test (2020-2032)

10.3.3.2. Market Revenue and Forecast, by Disease (2020-2032)

10.3.4. China

10.3.4.1. Market Revenue and Forecast, by Test (2020-2032)

10.3.4.2. Market Revenue and Forecast, by Disease (2020-2032)

10.3.5. Japan

10.3.5.1. Market Revenue and Forecast, by Test (2020-2032)

10.3.5.2. Market Revenue and Forecast, by Disease (2020-2032)

10.3.6. Rest of APAC

10.3.6.1. Market Revenue and Forecast, by Test (2020-2032)

10.3.6.2. Market Revenue and Forecast, by Disease (2020-2032)

10.4. MEA

10.4.1. Market Revenue and Forecast, by Test (2020-2032)

10.4.2. Market Revenue and Forecast, by Disease (2020-2032)

10.4.3. GCC

10.4.3.1. Market Revenue and Forecast, by Test (2020-2032)

10.4.3.2. Market Revenue and Forecast, by Disease (2020-2032)

10.4.4. North Africa

10.4.4.1. Market Revenue and Forecast, by Test (2020-2032)

10.4.4.2. Market Revenue and Forecast, by Disease (2020-2032)

10.4.5. South Africa

10.4.5.1. Market Revenue and Forecast, by Test (2020-2032)

10.4.5.2. Market Revenue and Forecast, by Disease (2020-2032)

10.4.6. Rest of MEA

10.4.6.1. Market Revenue and Forecast, by Test (2020-2032)

10.4.6.2. Market Revenue and Forecast, by Disease (2020-2032)

10.5. Latin America

10.5.1. Market Revenue and Forecast, by Test (2020-2032)

10.5.2. Market Revenue and Forecast, by Disease (2020-2032)

10.5.3. Brazil

10.5.3.1. Market Revenue and Forecast, by Test (2020-2032)

10.5.3.2. Market Revenue and Forecast, by Disease (2020-2032)

10.5.4. Rest of LATAM

10.5.4.1. Market Revenue and Forecast, by Test (2020-2032)

10.5.4.2. Market Revenue and Forecast, by Disease (2020-2032)

Chapter 11. Company Profiles

11.1. Genentech Inc.

11.1.1. Company Overview

11.1.2. Product Offerings

11.1.3. Financial Performance

11.1.4. Recent Initiatives

11.2. Sorenson Genomics, LLC

11.2.1. Company Overview

11.2.2. Product Offerings

11.2.3. Financial Performance

11.2.4. Recent Initiatives

11.3. Abbott Molecular

11.3.1. Company Overview

11.3.2. Product Offerings

11.3.3. Financial Performance

11.3.4. Recent Initiatives

11.4. Bayer Diagnostics

11.4.1. Company Overview

11.4.2. Product Offerings

11.4.3. Financial Performance

11.4.4. Recent Initiatives

11.5. Biocartis

11.5.1. Company Overview

11.5.2. Product Offerings

11.5.3. Financial Performance

11.5.4. Recent Initiatives

11.6. BioHelix

11.6.1. Company Overview

11.6.2. Product Offerings

11.6.3. Financial Performance

11.6.4. Recent Initiatives

11.7. Celera Genomics

11.7.1. Company Overview

11.7.2. Product Offerings

11.7.3. Financial Performance

11.7.4. Recent Initiatives

11.8. Genomic Health

11.8.1. Company Overview

11.8.2. Product Offerings

11.8.3. Financial Performance

11.8.4. Recent Initiatives

11.9. HTG Molecular Diagnostics

11.9.1. Company Overview

11.9.2. Product Offerings

11.9.3. Financial Performance

11.9.4. Recent Initiatives

11.10. PacBio

11.10.1. Company Overview

11.10.2. Product Offerings

11.10.3. Financial Performance

11.10.4. Recent Initiatives

Chapter 12. Research Methodology

12.1. Primary Research

12.2. Secondary Research

12.3. Assumptions

Chapter 13. Appendix

13.1. About Us

13.2. Glossary of Terms